Kmt2B — Lysine Methyltransferase 2B is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| KMT2B Gene | |
|---|---|
| Full Name | MLL2 (Mixed-Lineage Leukemia 2) / MLL4 |
| Chromosome | 19q13.12 |
| NCBI Gene ID | 9757 |
| OMIM | 606834 |
| Ensembl ID | ENSG00000167508 |
| UniProt ID | Q9UMN6 |
| Description | Histone H3K4 methyltransferase, transcriptional coactivator |
| Associated Diseases | Early-onset Dystonia, Parkinson's Disease, Rett Syndrome |
KMT2B (MLL2/MLL4) is another H3K4 methyltransferase that functions as a transcriptional coactivator. It is highly expressed in brain tissue and is essential for proper neuronal development. Mutations in KMT2B cause early-onset dystonia (DYT28), a movement disorder characterized by involuntary muscle contractions. KMT2B dysfunction may contribute to Parkinson's disease pathogenesis through altered transcription of dopaminergic neuronal survival genes.
The KMT2B gene encodes a protein that plays important roles in Early-onset Dystonia, Parkinson's Disease. This protein is involved in epigenetic regulation and transcriptional control mechanisms essential for normal neuronal function and survival.
KMT2B is widely expressed in the human brain, with high expression in:
Expression is regulated during development and declines with age, which may contribute to age-related neurodegenerative processes.
The protein product of KMT2B performs the following molecular functions:
Therapeutic targeting of KMT2B may involve:
The study of Kmt2B — Lysine Methyltransferase 2B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.